Chief Executive Pascal Soriot said the progress of a safety review into the trial subject will determine the timetable for vaccine progress. “We could still have a vaccine by the end of this year, early next year,” he told reporters during an online conference Thursday morning. AstraZeneca has signed deals with several governments, manufacturers and other institutions around the world to help it make and distribute its vaccine world-wide. An independent committee is reviewing potential safety concerns related to the sick U.K. trial participant, which led to the trial pause. The vaccine, which AstraZeneca has licensed from Oxford, is one of the most advanced efforts in the West.

Source: Wall Street Journal September 10, 2020 10:18 UTC